Rémi Laganier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rémi Laganier has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alexandre Manirakiza
Institut Pasteur of Bangui, Pasteur International Network
2 shared publications - Siméon P Njuimo
Institut Pasteur de Bangui, BP 923 Bangui, Central African Republic
2 shared publications - Alain Le Faou
Nancy-University
1 shared publication - Christophe Rogier
Institut Pasteur de Madagascar, Antananarivo, Madagascar.
1 shared publication - Djibrine Djallé
Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic
1 shared publication - Edith Narcisse Beyam
United Nations Population Fund, Bangui, Bangui, Central African Republic
1 shared publication
Latest Publications
- Open Access
- 7 January 2014
- Published by Springer Nature in Malaria Journal
- Vol. 13 (1) , 9
Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial
The efficacy of artemisinin-based combination therapy (ACT) has been established. The objective of the present study was to compare the efficacy and safety in the Central African Republic (CAR) of three commercially available artemisinin-based combinations, artemether + lumefantrine (AL), artesunate + sulphamethoxypyrazine-pyrimethamine (AS-SMP) and artesunate + amodiaquine (AS-AQ), with those of sulphadoxine-pyrimethamine + amodiaquine (SP-AQ), which was the first-line reference treatment in the country from 2004, until it was replaced by ACT in 2006 in accordance with changes in international recommendations based on resistance identified in other regions .
- 7 January 2014
- Published by Springer Nature in Malaria Journal
- Vol. 13 (1) , 9
Open AccessEfficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial
The efficacy of artemisinin-based combination therapy (ACT) has been established. The objective of the present study was to compare the efficacy and safety in the Central African Republic (CAR) of three commercially available artemisinin-based combinations, artemether + lumefantrine (AL), artesunate + sulphamethoxypyrazine-pyrimethamine (AS-SMP) and artesunate + amodiaquine (AS-AQ), with those of sulphadoxine-pyrimethamine + amodiaquine (SP-AQ), which was the first-line reference treatment in the country from 2004, until it was replaced by ACT in 2006 in accordance with changes in international recommendations based on resistance identified in other regions .
- Open Access
- 15 December 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 543
Clinical outcome of skin yaws lesions after treatment with benzathinebenzylpenicillin in a pygmy population in Lobaye, Central African Republic
International audience BACKGROUND: Yaws is a bacterial skin and bone infectious disease caused by Treponema pallidum pertenue. It is endemic, particularly among pygmies in Central African Republic. To assess the clinical cure rate after treatment with benzathinepenicillin in this population, we conducted a cohort survey of 243 patients in the Lobaye region. FINDINGS AND CONCLUSION: The rate of healing of lesions after 5 months was 95.9%. This relatively satisfactory level of therapeutic response implies that yaws could be controlled in the Central African Republic. Thus, reinforcement of the management of new cases and of contacts is suggested
- 15 December 2011
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 543
Open AccessClinical outcome of skin yaws lesions after treatment with benzathinebenzylpenicillin in a pygmy population in Lobaye, Central African Republic
International audience BACKGROUND: Yaws is a bacterial skin and bone infectious disease caused by Treponema pallidum pertenue. It is endemic, particularly among pygmies in Central African Republic. To assess the clinical cure rate after treatment with benzathinepenicillin in this population, we conducted a cohort survey of 243 patients in the Lobaye region. FINDINGS AND CONCLUSION: The rate of healing of lesions after 5 months was 95.9%. This relatively satisfactory level of therapeutic response implies that yaws could be controlled in the Central African Republic. Thus, reinforcement of the management of new cases and of contacts is suggested